Measuring serum levels in lung cancer patients may be useful in drug therapy monitoring.

Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.

The study prospectively evaluated levels of RANK, RANK-L and OPG transcripts in the peripheral blood of 49 consecutive patients with advanced breast, lung or prostate cancer.

In lung cancer, serum OPG levels in the BM and BM- groups were significantly increased compared with healthy controls.

OPG may be a potential driver of lung cancer cells and therefore might have potential in therapy and diagnostics.

We conclude that non-small cell lung cancer patients have a higher content of OPG in bronchoalveolar lavage fluid than healthy people.